CONFIDENCE ALABOSON: Open Payments
NPI 1750954970 · HOUSTON, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,686 in 130 payments from 47 companies in 2025. Trend: 2023 $3,375 · 2024 $3,164 · 2025 $3,686
Food & beverage: $3,138Education: $548
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 13 | $387 |
| Incyte Corporation | 5 | $257 |
| Novartis Pharmaceuticals Corporation | 8 | $222 |
| Eisai Inc. | 7 | $191 |
| Merck Sharp & Dohme LLC | 7 | $189 |
| GlaxoSmithKline, LLC. | 7 | $161 |
| Daiichi Sankyo Inc. | 7 | $154 |
| Alexion Pharmaceuticals, Inc. | 3 | $152 |
| E.R. Squibb & Sons, L.L.C. | 5 | $123 |
| Janssen Biotech, Inc. | 4 | $110 |
Products named: Lenvima, KEYTRUDA, Enhertu, OJJAARA, Fabhalta, VERZENIO, CALQUENCE, SOLIRIS.
Industry payments across TX — which companies pay providers there.
